*To the Editor:* Limited data are available to guide use of biologics for moderate to severe plaque psoriasis in the current coronavirus disease 2019 (COVID-19) health care landscape.[@bib1] ^,^ [@bib2] We aimed to further understand the rate of patient-driven biologic discontinuation in moderate to severe psoriasis because of concerns regarding COVID-19 complications. Furthermore, our goal was to add to the limited but increasing body of literature on whether biologic use should be considered a risk factor for greater susceptibility to COVID-19.

After research ethics approval, a multicenter retrospective study was undertaken of all patients from 2 tertiary academic hospitals affiliated with the University of Toronto, Canada, and a community practice in Hamilton, Canada. Inclusion criteria were patients aged 18 years or older with moderate to severe psoriasis who received at least 1 dose of a biologic before February 1, 2020. Data were retrospectively obtained from Patient Support Program case managers of all major suppliers of biologic agents for psoriasis. February 1, 2020, was the starting point of data collection (5 documented COVID-19 cases and 0 deaths in Canada) and patients were followed up until June 1, 2020 (91,703 cumulative cases and 7594 deaths).[@bib3]

As of February 1, 2020, there were 2095 patients receiving biologic therapy for psoriasis who met inclusion criteria. Total number of patients who temporarily discontinued their biologic at any point during the 4-month period because of COVID-19--related concerns was 23 (1.1%) ([Table I](#tbl1){ref-type="table"} ). Of the 23 patients who temporarily discontinued their biologic, 7 did so in February, 11 in March, 3 in April, and 2 in May. This corresponded to a total of 17 (0.81%), 18 (0.86%), and 18 (0.86%) patients discontinuing treatment at each of April 1, May 1, and June 1, 2020 timepoints, respectively. Biologic discontinuation by class included tumor necrosis factor α inhibitors (8/749, 1.07%), interleukin 12 and 23 inhibitors (5/371, 1.35%), interleukin 17 inhibitors (4/482, 0.83%), and interleukin 23 inhibitors (6/493, 1.22%) ([Table II](#tbl2){ref-type="table"} ). Mean duration of biologic treatment before discontinuation was 50.6 ± 35.7 months. Five patients who temporarily discontinued their biologic elected to restart the same biologic before June 1 compared with 18 who remained without treatment. All patients who restarted their biologic (5/5, 100%) did so because of a flare of their psoriasis. Of the 23 patients who temporarily discontinued treatment, 14 (60.9%) were men, mean age was 56.4 ± 12.6 years, and 1 (4.3%) also had psoriatic arthritis. Of the 2095 patients in our cohort (2072 \[98.9%\] of whom continued to receive a biologic throughout the entire follow-up period), 0 had a confirmed positive diagnosis of COVID-19. All patients who developed COVID-19--related symptoms received testing, results of which were negative. Of the 16 new biologic treatment initiations between April 1 and June 1, 2020, the majority were interleukin 17 inhibitors (n = 13, 81.2%), followed by tumor necrosis factor α inhibitors (n = 2, 12.5%) and interleukin 23 inhibitors (n = 1, 6.2%).Table IDemographics of psoriasis patients who temporarily discontinued biologic treatment because of coronavirus disease 2019 concernsDiscontinuation month, 2020BiologicSexAge, yearsDiagnosisDuration, monthsRestart before June 1FebruaryAdalimumabMan56Ps78YesAdalimumabMan70Ps90NoAdalimumabMan43Ps88NoGuselkumabMan56Ps19NoGuselkumabMan67Ps23NoInfliximabMan63Ps133NoUstekinumabMan45Ps43NoMarchAdalimumabMan46Ps92NoAdalimumabWoman65Ps + PsA83NoAdalimumabWoman65Ps43YesGuselkumabWoman64Ps24NoGuselkumabMan48Ps17NoGuselkumabWoman69Ps22NoIxekizumabWoman66Ps26YesIxekizumabMan70Ps23YesUstekinumabMan30Ps100NoUstekinumabMan49Ps2NoUstekinumabWoman51Ps36YesAprilGuselkumabMan56Ps18NoUstekinumabWoman71Ps35NoSecukinumabWoman73Ps56NoMayAdalimumabMan43Ps91NoIxekizumabWoman32Ps21No[^1][^2]Table IIPercentage of patient-driven temporary biologic treatment discontinuation during the coronavirus disease 2019 pandemicVariableCombinedAdalimumabBrodalumabCertolizumabEtanerceptGuselkumabInfliximabIxekizumabRisankizumabSecukinumabUstekinumabTotal patients[∗](#tbl2fnlowast){ref-type="table-fn"}2095290294636538848249105204371Discontinued before April 117 (0.81)5 (1.7)0005 (1.3)1 (2.1)2 (0.8)004 (1.08)Discontinued before May 118 (0.86)5 (1.7)0006 (1.5)1 (2.1)001 (0.5)5 (1.35)Discontinued before June 118 (0.86)5 (1.7)0006 (1.5)1 (2.1)1 (0.4)01 (0.5)4 (1.08)Total no. of restarts52000002001Combined all months[†](#tbl2fndagger){ref-type="table-fn"}23 (1.1)7 (2.4)0006 (1.5)1 (2.1)3 (1.2)01 (0.5)5 (1.35)[^3][^4][^5]

The results of this study demonstrate that the rate of patient-driven biologic discontinuation during the peak of COVID-19 cases in Canada remained low during the entire 4-month follow-up period. Although interleukin 17 inhibitors had the lowest rate of temporary discontinuation, there did not appear to be a major class-specific difference in rates. Our findings provide some of the earliest evidence supporting current COVID-19 biologic treatment guidelines and encourage continuation of biologics in asymptomatic patients with negative COVID-19 test results despite the risk of future outbreaks.[@bib4] ^,^ [@bib5] Discontinuation of treatment out of concerns about contracting COVID-19 is not supported because it may lead to decreased efficacy outcomes with reintroduction or a flare of psoriasis, as observed with our cohort. Low volumes of new biologic initiations highlight the need for improved access to nonurgent care during the pandemic.
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[^1]: Biologics reviewed included adalimumab, brodalumab, certolizumab, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, and ustekinumab.

[^2]: *Ps*, Psoriasis; *PsA*, psoriatic arthritis.

[^3]: Data are presented as No. (%) unless otherwise indicated.

[^4]: Total number of patients receiving a biologic for psoriasis as of February 1, 2020, and followed throughout the entire 4-month study period.

[^5]: Total number of patients who discontinued their biologic, including those who restarted before June 1.
